Skip to main
  1. Stocks
  2. Sight Sciences
  3. Forecast
SGHT

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences is supported by two distinct growth engines: the OMNI/SION glaucoma franchise and TearCare in dry eye, both of which showed strong Q3 momentum with total revenue of $24.9 million, up 25.2% year over year, and gross margin of 85.9%. The interventional glaucoma business grew 6.7% year over year, while dry eye surged 45% sequentially to $3.9 million, alongside rising unit volumes and active customers, indicating improving adoption and reimbursement traction. Management also lifted FY26 revenue guidance to $92 million-$93 million, and the combination of revenue growth, improving operating leverage, large addressable markets, and the $55.4 million Alcon judgment supports a constructive fundamental view.

Bears say

Sight Sciences is under pressure from persistent operating losses, with negative operating cash flow of ($12.7M) in 1H26 versus ($19.1M) in 1H25, a $38.4 million net loss in FY2025, and a $402.1 million accumulated deficit as of June 30, 2026, while management has offered no target date for cash-flow breakeven. Its balance sheet and financing profile add risk, as $79.8 million of cash is offset by a $40.0 million term loan bearing a 10.35% floor, with amortization starting February 1, 2027, plus restrictive covenants and secured claims on substantially all assets. Fundamentally, revenue concentration, weak growth visibility, reimbursement uncertainty, competitive pressure, tariff-sensitive supply chain exposure, and unresolved legal and patent issues make the outlook fragile despite OMNI’s EU MDR approval in December 2023.

Sight Sciences (SGHT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Sight Sciences (SGHT) Analyst Forecast & Price Prediction

Get the latest Sight Sciences (SGHT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Sight Sciences (SGHT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 7 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Sight Sciences (SGHT) Analyst Forecast & Price Prediction

Get the latest Sight Sciences (SGHT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Sight Sciences (SGHT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SGHT stock data and trends